This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
Advertisement
|
|
Advertisement
Advertisement
|
|
Advertisement
President's Blog: Light Up the Darkness
AST
In his latest blog post, AST President, Dr. Dan Salomon, discusses the first event of the new AST Power2Save initiative. On Nov. 1, more than 2,200 people joined the AST at a concert in Madison, Wisc., to see Scott MacIntyre, Joel Crouse, and The Band Perry perform, as well as to hear inspiring stories about the power of organ donation and the miracle of transplantation. Dr. Salomon described the event as "an amazing night of rocking country music to raise money and awareness for the AST's goals of advancing organ donation, public advocacy and research." Read the full blog post here .
Advertisement
T3: Register now for IPITA conference summary webinar on Nov. 19
AST
Webinars for the Timely Topics in Transplantation series are broadcast live on a Tuesday at 2 p.m. EST. Click here to register, members just use your AST username and password during registration to waive the fee!
It's time to renew your AST membership!
AST
To continue receiving all of the benefits AST membership has to offer through 2014, please login to the AST website now to pay your dues. If you have forgotten your login credentials, simply click the info@myAST.org with any questions.
PRODUCT SHOWCASE
 |
|
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
|
|
Stay warm with AST apparel!
AST
Starting to feel that November chill? Warm up with an AST fleece jacket or pullover. Starting at $35 and in sizes up to 3XL, we’ve got you covered! Shop the AST Store here.
Many liver transplant patients unable to afford meds
Medscape (login required)
One in 6 liver transplant recipients say they make trade-offs between buying food and their medication or they space out doses because they cannot afford them and try to make them last longer, a new study finds.
"Transplantations are not immune from these cost barriers," Marina Serper, MD, a transplant hepatology fellow at the University of Pennsylvania in Philadelphia, told Medscape Medical News. "Financial situations change. These things are important in the chronic disease population, and they're important in the transplant population as well."
New HCV drugs offer hope after transplant
MedPage Today
The advent of new all-oral regimens for hepatitis C (HCV) offers hope to patients who have undergone liver transplant and had the disease recur, a researcher said here.
Patients with hepatitis C who get a new liver universally have a recurrence of the disease in the new organ, according to Dr. Michael Charlton of the Mayo Clinic in Rochester.
First study of its kind shows that all-oral treatment regimen prevents hepatitis C recurrence in liver transplant recipients who received allografts
Newswire via Reuters
For the first time, researchers have been able to prevent the recurrence of hepatitis C virus (HCV) infection in a large proportion of patients (64 percent, n=25/39) who undergo liver transplantation for cirrhosis complicated by hepatocellular carcinoma (HCC). This success was achieved with an interferon-free treatment regimen containing the oral antivirals sofosbuvir, an investigational agent, and ribavirin.
|
Advertisement
|
 |
|
Astellas is entering its 20th year focusing on transplant immunology. Today we remain steadfast in our commitment to advancing the field. Tomorrow we will seek new possibilities to help improve the transplant experience. Together. Please visit astellas.us
|
|
Advertisement
|
 |
|
The University of Vermont/Fletcher Allen Health Care is seeking applications for a senior faculty member to join the Division of Nephrology. The candidate should be UNOS certified in kidney and pancreas transplants, experienced in educating nephrology fellows, growing transplant programs, and providing administrative leadership.
Apply Here
|
|
|
|
|
 |
|
|
The FlowSight offers high performance in a small package. Its innovative design increases signal and minimizes noise to provide unmatched fluorescence sensitivity. Twelve standard detection channels simultaneously produce brightfield, darkfield and up to ten channels of fluorescence imagery of every cell. More info
|
|
For nearly 30 years, physicians have trusted Viracor-IBT Laboratories to provide accelerated results, specialized expertise and exceptional service in transplant testing. Learn more at www.viracoribt.com.
|
|
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE
|
|
Study: Vitamin D deficiency and mortality in patients receiving dialysis
Journal of Renal Nutrition (login required)
Although several studies have shown poorer survival among individuals with 25-hydroxy (OH) vitamin D deficiency, data on patients receiving dialysis are limited. Using data from the Comprehensive Dialysis Study (CDS), researchers tested the hypothesis that patients new to dialysis with low serum concentrations of 25-OH vitamin D would experience higher mortality and hospitalizations.
Lung transplant 'patient 45' remembered 30 years on
CBC News
Lung transplant recipients, doctors and nurses are celebrating the 30th anniversary of the world's first successful lung transplant in Toronto.
In 1983, Tom Hall was the 45th patient in the world to receive a single lung at what was then Toronto General Hospital.
Tom Hall visits Paris, five years after his lung transplant. Before his successful operation, transplant recipients had not lived beyond a few days or weeks. (Courtesy University Health Network)
Hall lived more than six years — the first to survive for more than days or weeks after receiving the organ.
Looking to share your expertise?
MultiBriefs
In an effort to enhance the overall content of AST eNews, we’d like to include peer-written articles in future editions. As a member of AST, your knowledge of the industry lends itself to unprecedented expertise. And we're hoping you'll share this expertise with your peers through well-written commentary. Because of the digital format, there’s no word or graphical limit and our group of talented editors can help with final edits. If you’re interested in participating, please contact Ronnie Richard to discuss logistics.
Birmingham research tackles liver transplant failure
Health Canal
The re-infection of transplanted livers with hepatitis C virus (HCV) — which can irreparably damage the new organ — could be halted by administering a drug which blocks the virus entering the liver, research from the University of Birmingham being presented at the Liver Meeting demonstrates.
Missed last week's issue? See which articles your colleagues read most.
Does liver ischemic preconditioning in brain death donors induce kidney preconditioning? A retrospective analysis
NCBI
It is unclear whether ischemic preconditioning (IPC) of solid organs induces remote IPC (RIPC) in donors after brain death (DBD). In a recent study, outcomes in kidney recipients from 163 DBD in two randomized trials of liver IPC (5 min=62 and 10 min=101) were obtained retrospectively from the Scientific Registry of Transplant Recipients. Controls were kidney recipients from donors without IPC.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
Mobile version
